TOP TEN perturbations for 39868_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39868_at
Selected probe(set): 205663_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39868_at (205663_at) across 6674 perturbations tested by GENEVESTIGATOR:
precursor-B-ALL study 3 (TEL-AML1) / T-ALL study 3
Relative Expression (log2-ratio):-2.1202993Number of Samples:15 / 29
Experimental | precursor-B-ALL study 3 (TEL-AML1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
Control | T-ALL study 3 |
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
stem cell differentiation study 59 (iDRG; 12d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):2.0802164Number of Samples:4 / 4
Experimental | stem cell differentiation study 59 (iDRG; 12d) |
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper. | |
Control | normal embryonic stem cell sample (WA09) |
Undifferentiated WA09 embryonic stem cell samples. |
precursor-B-ALL study 3 (PAX5-rearranged) / T-ALL study 3
Relative Expression (log2-ratio):-2.0492744Number of Samples:6 / 29
Experimental | precursor-B-ALL study 3 (PAX5-rearranged) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
Control | T-ALL study 3 |
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
precursor-B-ALL study 3 (MLL-rearranged) / T-ALL study 3
Relative Expression (log2-ratio):-1.9488811Number of Samples:5 / 29
Experimental | precursor-B-ALL study 3 (MLL-rearranged) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
Control | T-ALL study 3 |
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
precursor-B-ALL study 3 (hyperdiploid) / T-ALL study 3
Relative Expression (log2-ratio):-1.9401302Number of Samples:17 / 29
Experimental | precursor-B-ALL study 3 (hyperdiploid) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
Control | T-ALL study 3 |
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
stem cell differentiation study 59 (iDRG; 15d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):1.9090681Number of Samples:4 / 4
Experimental | stem cell differentiation study 59 (iDRG; 15d) |
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 7 days. Further details are described in the paper. | |
Control | normal embryonic stem cell sample (WA09) |
Undifferentiated WA09 embryonic stem cell samples. |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample
Relative Expression (log2-ratio):-1.9060268Number of Samples:4 / 4
Experimental | B-CLL study 11 (DMSO) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
Control | vehicle (DMSO) treated normal B-cell sample |
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
precursor-B-ALL study 3 (BCR-ABL) / T-ALL study 3
Relative Expression (log2-ratio):-1.8480606Number of Samples:4 / 29
Experimental | precursor-B-ALL study 3 (BCR-ABL) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
Control | T-ALL study 3 |
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
Merkel cell carcinoma study 3 (primary) / normal skin tissue
Relative Expression (log2-ratio):1.799119Number of Samples:19 / 64
Experimental | Merkel cell carcinoma study 3 (primary) |
Primary tumor tissue from the skin of patients with Merkel cell carcinoma. | |
Control | normal skin tissue |
Normal skin samples from healthy donors. |
precursor-B-ALL study 2 (TEL-AML1) / T-ALL study 2
Relative Expression (log2-ratio):-1.7452669Number of Samples:21 / 13
Experimental | precursor-B-ALL study 2 (TEL-AML1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Dutch Childhood Oncology Group (DCOG). | |
Control | T-ALL study 2 |
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG). |